Literature DB >> 8264564

Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes.

A R Goeptar1, J M Te Koppele, E K Lamme, J M Piqué, N P Vermeulen.   

Abstract

The role of cytochrome P450 (CYP) in the one-electron reductive bioactivation of Adriamycin (ADR) (doxorubicin) was investigated in subcellular fractions of the rat liver. The rate of one-electron reduction of ADR to its semiquinone free radical (ADRSQ), measured by ESR, was 5-fold greater with phenobarbital (PB)-induced (PB microsomes) than with beta-naphthoflavone (beta NF)-induced (beta NF microsomes) rat liver microsomes under anaerobic conditions. ADRSQ formation was inhibited by SK&F 525-A and metyrapone (MP) in PB microsomes but was not significantly inhibited in beta NF microsomes. Under aerobic conditions, the formation of ADRSQ from ADR was diminished in microsomal incubations and concomitant reduction of molecular oxygen occurred instead. Whereas ADR-induced H2O2 formation in PB microsomes was strongly inhibited by SK&F 525-A and MP, only a slight inhibition was observed with 2-ethylnylnaphthalene and 1-ethynylpyrene in beta NF microsomes. In addition, MP produced strong inhibition of ADR-stimulated lipid peroxidation in PB microsomes, compared with beta NF microsomes. The idea that CYP2B1 was involved in the one-electron reduction of ADR in PB microsomes and in reconstituted systems of purified CYP2B1 and purified NADPH-CYP reductase (RED) under anaerobic conditions could be concluded from inhibition studies using SK&F 525-A and antibodies (KO1) against CYP2B enzymes. Moreover, it was calculated from reconstitution experiments using varying amounts of purified CYP2B1 and purified RED that the contribution of CYP2B1 to the one-electron reduction of ADR was similar to that of RED alone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264564

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport.

Authors:  Shoji Yamaguchi; Ying Lan Zhao; Masayuki Nadai; Hideo Yoshizumi; Xiaobo Cen; Shoko Torita; Kenji Takagi; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.

Authors:  William R Arnold; Javier L Baylon; Emad Tajkhorshid; Aditi Das
Journal:  Biochemistry       Date:  2017-12-12       Impact factor: 3.162

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Cytochromes P450 catalyze the reduction of α,β-unsaturated aldehydes.

Authors:  Immaculate Amunom; Laura J Dieter; Viola Tamasi; Jian Cai; Daniel J Conklin; Sanjay Srivastava; Martha V Martin; F Peter Guengerich; Russell A Prough
Journal:  Chem Res Toxicol       Date:  2011-07-29       Impact factor: 3.739

5.  Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2.

Authors:  Kazuhiko Hidemura; Ying Lan Zhao; Katsuki Ito; Akimasa Nakao; Yasuaki Tatsumi; Hiroaki Kanazawa; Kenzo Takagi; Michio Ohta; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Genetic variants contributing to daunorubicin-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  PEGylation and antioxidant effects of a human glutathione peroxidase 1 mutant.

Authors:  Guang-Yuan Zhang; Yan-Wei Wang; Li-Ying Guo; Liang-Ru Lin; Shao-Peng Niu; Chang-Hao Xiong; Jing-Yan Wei
Journal:  Aging (Albany NY)       Date:  2022-01-12       Impact factor: 5.682

8.  Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.

Authors:  S Khan; P J O'Brien
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

9.  Protective effect of p-coumaric acid against doxorubicin induced toxicity in H9c2 cardiomyoblast cell lines.

Authors:  Sunitha M Chacko; Kottayath G Nevin; R Dhanyakrishnan; B Prakash Kumar
Journal:  Toxicol Rep       Date:  2015-08-10

10.  A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.

Authors:  M A I Abou-El-Hassan; M J W E Rabelink; W J F van der Vijgh; A Bast; R C Hoeben
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.